The clinical need in the development of non-invasive methods for liver fibrosis assessment has emerged. At 3.0T, human in-vivo studies have demonstrated DCE-MRI using Exchange dual-input and dual-compartment pharmacokinetic model has potential to detect and assess the vascular permeability modification of liver fibrosis. DCE-MRI pharmacokinetic quantitative parameters including Ktrans, Ve and Vp can be used for diagnosing and staging liver fibrosis. Ktrans is the best index and predictor for discriminating normal livers from fibrotic livers.
This abstract and the presentation materials are available to members only; a login is required.